Page 27 - Pfizer

Pfizer, BioNTech to expand phase three trial for coronavirus vaccine

The US Food and Drug Administration (FDA) will have to approve the change in the Phase 3 Covid-19 vaccine trial before it goes into effect

US, European Covid-19 vaccine developers pledge to uphold testing rigour

The promise to play by established rules underlines a highly politicised debate over what action is needed to rein in Covid-19 quickly and to jumpstart global business and trade

BioNTech, Pfizer begin German part of coronavirus vaccine study

Biotech firm BioNTech said on Monday it widened an ongoing pivotal global study of its Covid-19 vaccine candidate to include testing in its home country of Germany

Pfizer, BioNTech Covid-19 vaccine on track for regulatory review in October

The companies said the vaccine was well tolerated with mild to moderate fever in fewer than 20% of the participants

Covid-19 vaccine makers must deliver to US in time to get full payments

The Cambridge, Massachusetts, biotech's $1.5-billion deal pays out in full if its vaccine receives regulatory clearance by January 31, 2021

Pfizer-BioNTech vaccine candidate induces robust immune response: Study

It is one of several RNA vaccine candidates that are being studied in parallel for selection to advance to a trial of their safety and efficacy

Rich nations rush to lock up Covid vaccines: What about rest of the world?

Moves by the US and UK to secure supplies from Sanofi and partner GlaxoSmithKline Plc, and another pact between Japan and Pfizer Inc., are the latest in a string of agreements

Pfizer, BioNTech to supply 120 mn doses of coronavirus vaccine to Japan

BioNTech and Pfizer on Monday began a large, late-stage trial of their vaccine candidate to demonstrate its efficacy

Pfizer and BioNTech start late-stage study of lead Covid-19 shot

The move pushes the New York-based pharmaceutical giant and its German partner closer to bringing a vaccine to market, and places them alongside frontrunners like Moderna Inc

Pfizer optimistic about rebound in drug sales, raises 2020 profit forecast

The report comes at the start of a busy week of US pharmaceutical earnings, with investors focusing on updates on the development of vaccines and treatments for the pandemic

Moderna, Pfizer begin Covid-19 vaccine trials, eye year-end launches

The study is expected to include about 120 sites globally and could include up to 30,000 participants. It will include regions heavily impacted by Covid-19

Pfizer profit before tax down marginally to Rs 173 crore in June quarter

Revenue stood at Rs 514.89 crore against Rs 544.40 crore for the same period a year ago

US to pay Pfizer, BioNTech $1.95 bn for 100 mn Covid-19 vaccine doses

The companies will not receive any money from the government unless their vaccine succeeds in large clinical trials

S&P 500 gains on promising Covid-19 vaccine data, more stimulus hopes

US drugmaker Pfizer and German biotech firm BioNTech reported additional data from their experimental Covid-19 vaccine that showed it was safe and induced an immune response in patients

Pfizer-BioNTech potential Covid-19 vaccine shows promise in additional data

The companies said the data also demonstrated an induction of high level of T-cell response against the novel coronavirus

Britain signs deals with Pfizer, BioNTech, Valneva for Covid-19 vaccines

Deals follow a previously announced agreement with AstraZeneca for the firm to produce 100 million doses of its potential vaccine being developed in partnership with the University of Oxford

Early trial of Covid-19 vaccines by Pfizer, BioNtech promising: Scientists

The research said patients treated with the vaccine candidate produced nearly 1.8 to 2.8 fold greater levels of antibodies that could neutralise SARS-CoV-2

Pfizer, BioNTech's Covid-19 drug shows encouraging results in early tests

With its other potential candidates still in the earliest stage of testing, Pfizer aims to open a large-scale study this summer but can't yet say which shot is best to include

S&P, Nasdaq higher on Covid-19 vaccine hopes, improving economic data

A Covid-19 vaccine developed by Pfizer Inc and German biotech firm BioNTech showed promise and was found to be well tolerated in early-stage human trials

J&J to begin human trials of Covid-19 vaccine in second half of July

The company has already signed deals with the US government to create enough manufacturing capacity to produce more than 1 billion doses of its vaccine through 2021